Research programme: anti-inflammatory therapeutics - KBP BioSciences
Alternative Names: KBP-7026; KBP-7306; KBP-7536Latest Information Update: 25 Apr 2023
At a glance
- Originator KBP Biosciences
- Class Anti-inflammatories; Antirheumatics; Eye disorder therapies
- Mechanism of Action Chemokine receptor antagonists; Formyl peptide receptor antagonists; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Dry eyes; Rheumatoid arthritis
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Asthma in China (PO) (KBP BioSciences pipeline, April 2023)
- 25 Apr 2023 Discontinued - Preclinical for Chronic obstructive pulmonary disease in China (PO) (KBP BioSciences pipeline, April 2023)
- 25 Apr 2023 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (PO) (KBP BioSciences pipeline, April 2023)